| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Wataru Yamamoto, Tadayoshi Mikami, Hiroyuki Iwamur. Involvement of central cannabinoid CB2 receptor in reducing mechanical allodynia in a mouse model of neuropathic pain. European journal of pharmacology. vol 583. issue 1. 2008-05-27. PMID:18279850. |
furthermore, the analgesic effects of intrathecal jwh133 (100 nmol/mouse) were absent in cannabinoid cb2 receptor knockout mice. |
2008-05-27 |
2023-08-12 |
mouse |
| Wataru Yamamoto, Tadayoshi Mikami, Hiroyuki Iwamur. Involvement of central cannabinoid CB2 receptor in reducing mechanical allodynia in a mouse model of neuropathic pain. European journal of pharmacology. vol 583. issue 1. 2008-05-27. PMID:18279850. |
these results suggest that the activation of central, but not peripheral, cannabinoid cb2 receptors play an important role in reducing mechanical allodynia in a mouse model of neuropathic pain. |
2008-05-27 |
2023-08-12 |
mouse |
| Akiko Shiratsuchi, Ikuko Watanabe, Hiroko Yoshida, Yoshinobu Nakanish. Involvement of cannabinoid receptor CB2 in dectin-1-mediated macrophage phagocytosis. Immunology and cell biology. vol 86. issue 2. 2008-05-22. PMID:17909562. |
an agonist of the cannabinoid receptors cb1 and cb2 also stimulated the phagocytosis of zymosan. |
2008-05-22 |
2023-08-12 |
mouse |
| Akira Kikuchi, Katsuyo Ohashi, Yutaka Sugie, Hiromi Sugimoto, Hirofumi Omur. Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity. Journal of pharmacological sciences. vol 106. issue 2. 2008-05-22. PMID:18270474. |
pharmacological evaluation of a novel cannabinoid 2 (cb2) ligand, pf-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity. |
2008-05-22 |
2023-08-12 |
human |
| M Isolde Rudolph, Yadira Boza, Roger Yefi, Sandra Luza, Edilia Andrews, Alicia Penissi, Pablo Garrido, I Gina Roja. The influence of mast cell mediators on migration of SW756 cervical carcinoma cells. Journal of pharmacological sciences. vol 106. issue 2. 2008-05-22. PMID:18296861. |
supernatants from sw756 cells stimulated lad2 cell degranulation, which in turn was inhibited by cannabinoids acting via cb2 receptors. |
2008-05-22 |
2023-08-12 |
Not clear |
| F J Bermúdez-Silva, J Suárez, E Baixeras, N Cobo, D Bautista, A L Cuesta-Muñoz, E Fuentes, P Juan-Pico, M J Castro, G Milman, R Mechoulam, A Nadal, F Rodríguez de Fonsec. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia. vol 51. issue 3. 2008-05-21. PMID:18092149. |
we examined the presence of functional cannabinoid receptors 1 and 2 (cb1, cb2) in isolated human islets, phenotyped the cells producing cannabinoid receptors and analysed the actions of selective cannabinoid receptor agonists on insulin, glucagon and somatostatin secretion in vitro. |
2008-05-21 |
2023-08-12 |
human |
| Fabrizio Montecucco, Fabienne Burger, François Mach, Sabine Steffen. CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. American journal of physiology. Heart and circulatory physiology. vol 294. issue 3. 2008-05-15. PMID:18178718. |
the aim of this study was to investigate if activation of cb2 cannabinoid receptors would modulate the chemotactic response of human monocytes. |
2008-05-15 |
2023-08-12 |
human |
| John P Buchweitz, Peer W F Karmaus, Kurt J Williams, Jack R Harkema, Norbert E Kaminsk. Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence and presence of Delta9-tetrahydrocannabinol. Journal of leukocyte biology. vol 83. issue 3. 2008-05-14. PMID:18073275. |
targeted deletion of cannabinoid receptors cb1 and cb2 produced enhanced inflammatory responses to influenza a/pr/8/34 in the absence and presence of delta9-tetrahydrocannabinol. |
2008-05-14 |
2023-08-12 |
mouse |
| Estera Páldyová, Erika Bereczki, Miklós Sántha, Tibor Wenger, Anna Borsodi, Sándor Benyh. Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors. Neurochemistry international. vol 52. issue 1-2. 2008-05-05. PMID:17698254. |
noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via cb2 cannabinoid receptors. |
2008-05-05 |
2023-08-12 |
mouse |
| Estera Páldyová, Erika Bereczki, Miklós Sántha, Tibor Wenger, Anna Borsodi, Sándor Benyh. Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors. Neurochemistry international. vol 52. issue 1-2. 2008-05-05. PMID:17698254. |
while noladin ether (ne) demonstrates agonist activity at cb1 cannabinoid receptors, recent data indicate that ne acts as a full agonist at cb2 cannabinoid receptors too. |
2008-05-05 |
2023-08-12 |
mouse |
| Estera Páldyová, Erika Bereczki, Miklós Sántha, Tibor Wenger, Anna Borsodi, Sándor Benyh. Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors. Neurochemistry international. vol 52. issue 1-2. 2008-05-05. PMID:17698254. |
taken together, our data suggest that the ne caused pronounced decrease in the activity of mor is mediated via cb2 cannabinoid receptors. |
2008-05-05 |
2023-08-12 |
mouse |
| Eva de Lago, Javier Fernández-Rui. Cannabinoids and neuroprotection in motor-related disorders. CNS & neurological disorders drug targets. vol 6. issue 6. 2008-05-02. PMID:18220777. |
in both disorders, the key mechanisms involved in the neuroprotection provided by cannabinoids include cannabinoid receptor-independent effects aimed at reducing the oxidative injury, and also cannabinoid 2 receptors (cb2)-mediated effects exerted by regulating the influence of reactive microglia on neuronal homeostasis. |
2008-05-02 |
2023-08-12 |
Not clear |
| Eva de Lago, Javier Fernández-Rui. Cannabinoids and neuroprotection in motor-related disorders. CNS & neurological disorders drug targets. vol 6. issue 6. 2008-05-02. PMID:18220777. |
there is evidence that both cannabinoid 1 receptors (cb1) and cb2 may afford a protective effect in this disease due to their immunomodulatory, anti-inflammatory and anti-excitotoxic properties. |
2008-05-02 |
2023-08-12 |
Not clear |
| Eva de Lago, Javier Fernández-Rui. Cannabinoids and neuroprotection in motor-related disorders. CNS & neurological disorders drug targets. vol 6. issue 6. 2008-05-02. PMID:18220777. |
lastly, neuroprotective effects of cannabinoids exerted by the activation of cb1 but also cb2 receptors have been also identified in amyotrophic lateral sclerosis (als), another degenerative disease characterized by the selective death of spinal motoneurons. |
2008-05-02 |
2023-08-12 |
Not clear |
| F Teixeira-Clerc, B Julien, P Grenard, J Tran Van Nhieu, V Deveaux, C Hezode, A Mallat, S Lotersztaj. [The endocannabinoid system as a novel target for the treatment of liver fibrosis]. Pathologie-biologie. vol 56. issue 1. 2008-04-18. PMID:17412522. |
the cannabinoid system comprises specific g protein-coupled receptors (cb1 and cb2), exogenous (marijuana-derived cannabinoids) and endogenous (endocannabinoids) ligands, and a machinery dedicated to endocannabinoid synthesis and degradation. |
2008-04-18 |
2023-08-12 |
Not clear |
| Monica Bari, Sergio Oddi, Chiara De Simone, Paola Spagnolo, Valeria Gasperi, Natalia Battista, Diego Centonze, Mauro Maccarron. Type-1 cannabinoid receptors colocalize with caveolin-1 in neuronal cells. Neuropharmacology. vol 54. issue 1. 2008-04-18. PMID:17714745. |
type-1 (cb1) and type-2 (cb2) cannabinoid receptors belong to the rhodopsin family of g protein-coupled receptors, and are activated by endogenous lipids termed "endocannabinoids". |
2008-04-18 |
2023-08-12 |
Not clear |
| Amir Reza Hajrasouliha, Sina Tavakoli, Mehdi Ghasemi, Pejman Jabehdar-Maralani, Hamed Sadeghipour, Farzad Ebrahimi, Ahmad Reza Dehpou. Endogenous cannabinoids contribute to remote ischemic preconditioning via cannabinoid CB2 receptors in the rat heart. European journal of pharmacology. vol 579. issue 1-3. 2008-04-15. PMID:17950273. |
endogenous cannabinoids contribute to remote ischemic preconditioning via cannabinoid cb2 receptors in the rat heart. |
2008-04-15 |
2023-08-12 |
rat |
| Vincenzo Micale, Carmen Mazzola, Filippo Drag. Endocannabinoids and neurodegenerative diseases. Pharmacological research. vol 56. issue 5. 2008-04-08. PMID:17950616. |
the cannabinoid cb1 and cb2 receptors, the endogenous endocannabinoid (ec) ligands anandamide (aea) and 2-arachidonylethanolamide, and the degradative enzymes fatty acid amide hydrolase (faah) and monoglyceride lipase (ml) are key elements of the ec system implicated in different physiological functions including cognition, motor activity and immune responses. |
2008-04-08 |
2023-08-12 |
Not clear |
| Vincenzo Micale, Carmen Mazzola, Filippo Drag. Endocannabinoids and neurodegenerative diseases. Pharmacological research. vol 56. issue 5. 2008-04-08. PMID:17950616. |
decrease of neuronal cannabinoid cb1 receptors, increase of glial cannabinoid cb2 receptors and over-expression of faah in astrocytes) in experimental models of ad as well as in post-mortem brain tissue of ad patients, suggesting its possible role in inflammatory processes and in neuroprotection. |
2008-04-08 |
2023-08-12 |
Not clear |
| Vincenzo Micale, Carmen Mazzola, Filippo Drag. Endocannabinoids and neurodegenerative diseases. Pharmacological research. vol 56. issue 5. 2008-04-08. PMID:17950616. |
we focus on the effects of compounds modulating the ec system (agonists/antagonists of cannabinoid cb1 and cb2 receptors, or inhibitors of ecs metabolism processes) on the symptoms and/or progression of neurodegenerative diseases. |
2008-04-08 |
2023-08-12 |
Not clear |